Novartis Lowers Mid-Term Growth Guidance to 5% Through 2031
Novartis targets 5% annual sales growth through 2031 as key drugs face patent expiries, while raising peak forecasts for Kesimpta, Scemblix and Leqvio.
Already have an account? Sign in.